secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eiger BioPharmaceuticals, Inc. (—)
CIK:        0001305253
Form:       8-K
Filed at:   2024-09-09T23:59:59+00:00
Accession:  0001193125-24-215909
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 1.03, 3.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eiger BioPharmaceuticals Chapter 11 liquidation plan confirmed; all equity cancelled
--------------------------------------------------------------------------------

- Bankruptcy Court entered confirmation order on Sept 5, 2024, for Fifth Amended Joint Plan of Liquidation.
- All 1,480,797 shares of common stock to be cancelled on effective date; no recovery for equity holders.
- Assets sold: Zokinvy to Sentynl, Avexitide to Amylyx, Lonafarnib/Lambda to Eiger InnoTherapeutics.
- As of July 31, 2024, Debtors reported ~$65.6M assets and ~$40M liabilities (unaudited).
- Liquidating Trustee and Plan Administrator to wind down operations and administer trust assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524215909/0001193125-24-215909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524215909/d887098d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-215909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer